Evotec reaffirmed 2026 guidance: Evotec stock gains 2.14 percent

Published on 10/26/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guidance stays EUR 570 million to EUR 610 million. Evotec stock costs EUR 2.87 on October 26, 2026, 2.14 percent above its Xetra close.

Guidance and market reaction

Evotec expected EUR 465.0 million in nine-month revenue on October 13, 2026.
The company retained 2026 revenue guidance of EUR 570 million to EUR 610 million.
Evotec stock trades at EUR 2.87 at 9:45 a.m. CEST at Lang & Schwarz on October 26, 2026, 2.14 percent above the Xetra close of October 23, 2026.

Isometrische 3D-Illustration einer Wirkstoffforschungs-Wertschöpfungskette mit Molekülen und Laborrobotern — Isometrische 3D-Grafik zeigt den Wirkstoffscreening-Prozess der Biotech-Branche von Evotec SE, ISIN DE0005664809, als Wertschöpfungskette, Illustration mit AI erstellt.

Evotec SE (ISIN DE0005664809) was trading at EUR 2.87 at Lang & Schwarz on October 26, 2026, at 9:45 a.m. CEST, 2.14 percent above the Xetra close of October 23, 2026, at EUR 2.81. The company retained its 2026 revenue and adjusted EBITDA outlook after preliminary nine-month figures exceeded market expectations, according to Stock-World on October 26, 2026.

Preliminary figures beat expectations

For the first nine months of 2026, Evotec indicated revenue of EUR 465.0 million and adjusted EBITDA of minus EUR 42.8 million. Both figures exceeded market expectations, but the company attributed the difference largely to the timing of consensus estimates rather than to a higher full-year outlook, as Boerse Express reported on October 24, 2026.

What does the outlook mean for losses?

Evotec continues to guide for 2026 revenue of EUR 570 million to EUR 610 million and adjusted EBITDA of minus EUR 70 million to minus EUR 105 million. At constant exchange rates, the revenue range is EUR 595 million to EUR 635 million, while adjusted EBITDA is expected at minus EUR 60 million to minus EUR 90 million. The figures keep the central issue clear: better interim performance has not yet translated into a smaller full-year operating loss.

Three dated steps toward results

On October 13, 2026, Evotec indicated nine-month revenue of EUR 465.0 million and adjusted EBITDA of minus EUR 42.8 million. On October 14, 2026, RBC Capital Markets confirmed an Outperform rating and a EUR 10.00 price target, according to Boerse Global. On October 24, 2026, Boerse Express highlighted the unchanged revenue range of EUR 570 million to EUR 610 million and the adjusted EBITDA range of minus EUR 70 million to minus EUR 105 million.

Next dates include November reporting

Joanna Holbrook's appointment as chief scientific officer and board member takes effect on November 1, 2026, according to Boerse Express. Evotec is scheduled to publish its third-quarter and nine-month results on November 5, 2026, according to Stock-World.

Stock trades above Xetra close

Evotec's market capitalization was EUR 510.4 million as of October 26, 2026, while its 52-week range stood at EUR 2.41 to EUR 7.30. The valuation remains tied to whether the November report confirms a durable improvement beyond the timing effect cited for the preliminary figures.

Evotec was trading at EUR 2.87 at Lang & Schwarz on October 26, 2026, at 9:45 a.m. CEST, 2.14 percent above the Xetra close of October 23, 2026, at EUR 2.81. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.